Open label, healthy volunteers, ADME study with single oral administration of [14C] AZD5069

Study identifier:D3550C00013

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase I, Open-Label Study to Characterise the Absorption, Distribution, Metabolism and Excretion following a Single Oral Dose of [14C]AZD5069 in Healthy Male Volunteers

Medical condition

Healthy

Phase

Phase 1

Healthy volunteers

Yes

Study drug

[14C] AZD5069

Sex

Male

Actual Enrollment

Study type

Interventional

Age

50 Years +

Date

Study Start Date: 01 May 2011

Primary Completion Date: 01 Jul 2011

Study Completion Date: 01 Jul 2011

Study design

Allocation: N/A
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science

Verification:

Verified 01 Jun 2015 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

Location

Research Site

London, United Kingdom

Arms	Assigned Interventions
Experimental: 1 [14C] AZD5069	Drug: [14C] AZD5069 Single 120 mg oral dose administered on Day 1

Documents available

CSR Synopsis
Download
Trial Results Summaries
Available here

Contacts

Contact

Quintiles Drug Research Unit at Guys Hospital

+44 20 7910 7877

suresh.babu@quintiles.com

Investigators

Principal Investigator

Prof. Tim Mant

Quintiles Drug Research Unit at Guy's Hospital